Welcome to our dedicated page for Kailera Therapeutics SEC filings (Ticker: KLRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Kailera Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Kailera Therapeutics's regulatory disclosures and financial reporting.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. filed an initial ownership report as a ten percent owner of Kailera Therapeutics, Inc.. The filing shows indirect ownership of 1 share of common stock through Hengrui (USA) Ltd. and direct holdings of Series A-2 preferred securities.
The Series A-2 convertible preferred stock is convertible into 9,477,719 shares of common stock, and the Series A-2 convertible non-voting preferred stock is convertible into 2,034,133 shares of common stock. According to the disclosure, this preferred stock is convertible at the holder’s election, has no expiration date, and will automatically convert into common shares immediately prior to the closing of Kailera’s initial public offering of common stock.
This Form 3 records existing ownership positions and does not report any new purchases or sales.
Kailera Therapeutics, Inc. director and more than ten percent owner Dr. Adam Koppel filed an initial Form 3 reporting indirect holdings of the company’s preferred stock through BCLS Fund IV Investments, LP. These holdings consist of Series A-1 and Series B Preferred Stock that are each convertible into Common Stock on a 1:1 basis.
Footnotes explain that each preferred share is convertible at the holder’s option and will automatically convert into Common Stock upon the closing of Kailera Therapeutics’ initial public offering, with no expiration date. Dr. Koppel is a partner of Bain Capital Life Sciences Investors, LLC, the ultimate general partner of BCLS Fund IV Investments, and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Kailera Therapeutics, Inc. reported that Bain Capital–affiliated entities are indirect ten percent owners through holdings of the company’s Series B Preferred Stock. The filing shows 17,857,143 shares of Series B Preferred Stock, which are convertible into an equal number of common shares on a 1:1 basis.
These preferred shares are held directly by BCPE Perseus Investor, LP, while related Bain Capital entities are positioned upstream as general partners or managing members and may be deemed to share voting and dispositive power. The Bain entities each disclaim beneficial ownership beyond their pecuniary interest in these securities.
Kailera Therapeutics, Inc. filed an initial ownership report showing that Bain Capital Life Sciences–affiliated entities are indirect ten percent owners through preferred stock holdings. BCLS Fund IV Investments, L.P. holds Series A-1 and Series B Preferred Stock that are each convertible into Common Stock on a 1:1 basis and automatically convert upon the closing of Kailera’s initial public offering, with no expiration date.
The filing reports 4,145,768 underlying shares of Common Stock from Series B Preferred Stock and 16,875,000 underlying shares of Common Stock from Series A-1 Preferred Stock, all held indirectly. Upstream Bain Capital Life Sciences entities may be deemed to share voting and dispositive power over these securities while disclaiming beneficial ownership except to the extent of their pecuniary interest.
Kailera Therapeutics, Inc. executive Paul D. Burgess filed an initial ownership report showing three direct stock option positions in the company’s common stock. These options give rights to acquire 325,491 shares at an exercise price of $7.24, and 191,444 and 285,307 shares each at $5.25 per share.
The options tied to 285,307 shares vested 25% on December 9, 2025, with the rest in 36 monthly installments, while those for 191,444 shares vested 25% on September 16, 2025 on a similar schedule. The 325,491‑share grant is scheduled to vest 25% on November 5, 2026, then in 36 monthly installments, all subject to Burgess’s continued service.
Kailera Therapeutics, Inc. filed an initial ownership report for Chief Medical Officer Scott M. Wasserman, showing existing stock option holdings in the company. These options give him the right to buy common shares at exercise prices of $7.24 and $5.25 per share, with expirations in 2034 and 2035. The footnotes explain that each grant vests 25% on an initial vesting date in 2025 or 2026, then in 36 substantially equal monthly installments, conditioned on his continued service.
Kailera Therapeutics, Inc. received an initial ownership report showing significant preferred stock holdings by funds managed by RTW Investments, LP, with Roderick Wong also listed as a reporting person and a ten percent owner.
The affiliated RTW funds hold Series A Preferred Stock convertible into 8,250,000 shares of Common Stock and Series B Preferred Stock convertible into 2,026,820 shares of Common Stock. Each preferred share has no expiration date and will automatically convert into Common Stock on a 1-for-1 basis immediately prior to the closing of Kailera’s initial public offering for no additional consideration. The securities are held indirectly through RTW-managed funds, and the reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.
Kailera Therapeutics director Martin Mackay filed an initial ownership report showing a stock option position rather than a new share purchase or sale. The option covers 170,194 shares of Common Stock with an exercise price of $11.56 per share and expires on March 10, 2036.
According to the vesting terms, 25% of the total shares vest on March 10, 2027, with the remaining options vesting in 36 substantially equal monthly installments, contingent on his continued service with the company.
Kailera Therapeutics, Inc. director Liu Yuting filed an initial Form 3, which is a statement of beneficial ownership by an insider. The filing shows no reported transactions, no derivative positions, and no buy, sell, acquire, or dispose activity in the securities of Kailera Therapeutics at this time.
Kailera Therapeutics, Inc. reported the initial equity holdings of Chief People Officer Paula Cloghessy on a Form 3, showing multiple stock option awards to purchase common stock. These options give her the right to buy shares at exercise prices between $5.25 and $7.24 per share.
The holdings include options over 230,728 underlying shares at an exercise price of $7.24 expiring in 2035, 95,350 shares at $5.40 expiring in 2035, and two grants of 86,150 and 128,388 shares at $5.25 expiring in 2034. Footnotes state each grant vests 25% on specified initial vesting dates in 2025 or 2026, then in 36 substantially equal monthly installments, subject to her continued service.